Výsledky vyhledávání - "James E. Bradof"

Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial

Autor: Dana S. Thompson, Joan B. Erland, John D. Hainsworth, Thomas W. Twele, James E. Bradof, M. Patrick Stagg, John H. Barton, F. Anthony Greco

Publikováno v: Clinical Lung Cancer. 5:33-38

The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the combination of weekly docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC) who are either elderly or have poor performance stat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8f4ebb9258cde541dbfe68e7cbf47e
https://doi.org/10.3816/clc.2003.n.019

Zobrazit plný text záznamu

Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study

Autor: Lisa H. Morrissey, John H. Barton, Sharlene Litchy, Daniel C. Scullin, John D. Hainsworth, Howard A. Burris, Joan B. Erland, Paul Richards, F. Anthony Greco, James E. Bradof

Publikováno v: Journal of Clinical Oncology. 20:1651-1656

PURPOSE: To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site. PATIENTS AND METHODS: One hundred twenty

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3313f85212549dd168c9f2f5869193c
https://doi.org/10.1200/jco.2002.20.6.1651

Zobrazit plný text záznamu

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma

Autor: F. Anthony Greco, Margaret N. Baker, James E. Bradof, John D. Hainsworth, Howard A. Burris, Frederic T. Billings

Publikováno v: Cancer. 92:2391-2398

BACKGROUND The current study was conducted to evaluate the feasibility, toxicity, and efficacy of weekly docetaxel when paired with either gemcitabine or vinorelbine as the second-line treatment of patients with advanced nonsmall cell lung carcinoma.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::00527451dbb168957007e6f30dd14240
https://doi.org/10.1002/1097-0142(20011101)92:9<2391::aid-cncr1587>3.0.co

Zobrazit plný text záznamu

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma

Autor: Lisa H. Morrissey, John D. Hainsworth, Sharlene Litchy, John H. Barton, Howard A. Burris, James E. Bradof, F. Anthony Greco

Publikováno v: Cancer. 89:328-333

BACKGROUND Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. In the current Phase II trial, the authors evaluated the feasibility, toxicity, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c55d389bd727d5831d33ff47111e119f
https://doi.org/10.1002/1097-0142(20000715)89:2<328::aid-cncr17>3.0.co

Zobrazit plný text záznamu

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

Autor: Suzanne F. Jones, F. Anthony Greco, Howard A. Burris, David R. Spigel, James R. Rubinsak, Emily R. Burkett, Natalie R. Dickson, Melodie Thomas, Daniel C. Scullin, Joseph E. Brierre, Denise A. Yardley, John D. Hainsworth, James E. Bradof

Publikováno v: Clinical lung cancer. 7(2)

BACKGROUND: Patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS: Seventy-two patients with p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1741cf04deea854e4283a69b19ecd2c
https://pubmed.ncbi.nlm.nih.gov/16179100

Zobrazit plný text záznamu

Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network

Autor: John D. Hainsworth, James E. Bradof, John H. Barton, F. Anthony Greco, Sharlene Litchy, Gerry Ann Houston, Robert C. Hermann

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(9)

Purpose: To assess the efficacy and toxicity of first-line single-agent rituximab, followed by re-treatment with rituximab at 6-month intervals, in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::679ad9da8718a474dec0db6f2c2fc8c6
https://pubmed.ncbi.nlm.nih.gov/12721250

Zobrazit plný text záznamu

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

Autor: John D. Hainsworth, F. Anthony Greco, Howard A. Burris, Margaret N. Baker, Denise A. Yardley, James E. Bradof, Joan B. Erland, Timothy Sullivan, L A Kalman, Manuel Grimaldi

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(15)

PURPOSE: To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer. PATIENTS AND METHODS: Forty-one patients with advanced breast cancer who were either over the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20544708d16e744fb8ac824b7e5b4550
https://pubmed.ncbi.nlm.nih.gov/12409345

Zobrazit plný text záznamu

Phase II study of amonafide in advanced pancreatic adenocarcinoma

Autor: James L. Abbruzzese, Richard Pazdur, Bernard Levin, James E. Bradof, Karen Daugherty, Jaffer A. Ajani, Kaye A. Linke, Rodger J. Winn

Publikováno v: Investigational new drugs. 9(4)

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1da10993727dea9b03c59315eedf497
https://pubmed.ncbi.nlm.nih.gov/1804812

Zobrazit plný text záznamu

Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network

Autor: E. Raefsky, James E. Bradof, John D. Zubkus, W. H. Liggett, Marshall T. Schreeder, David R. Spigel, John D. Hainsworth, D. A. Yardley, F. A. Greco, D. Petrone, D. V. Woytowitz

Publikováno v: Journal of Clinical Oncology. 23:7050-7050

7050 Background: Preclinical studies have demonstrated VEGF expression in SCLC, a target that may predict response to treatment with anti-angiogenic agents such as B. Few trials have incorporated these agents into the treatment of SCLC, providing rat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f6de8eec6a35a325d844e7b8e709c51
https://doi.org/10.1200/jco.2005.23.16_suppl.7050

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání